Cognizant Technology Solutions has delivered one of its sharpest weekly moves in years, with the Q2 earnings print on July 29 triggering a rapid repositioning across short sellers, options traders, and the analyst community simultaneously.
The most dramatic shift is in short positioning. Short interest has fallen 12.2% in a week — from roughly 63 million shares to 55.1 million — bringing the free float short to 11.4%, down from a recent peak near 13.8% in mid-July. That unwinding accelerated into and through the earnings date, and it has coincided with a 15.3% weekly gain and a 25.7% monthly rally to $50.31. The borrow market tells you this is orderly exit, not mechanical squeeze: availability is running at 578%, meaning roughly six shares remain available to borrow for every one currently lent out, and the cost to borrow has eased to 0.39% — its lowest level in six weeks. Shorts leaving now face no friction; they are choosing to go.
Options positioning reinforced the bullish lean. The put/call ratio collapsed to 0.976 on July 28, nearly 3.7 standard deviations below its 20-day average of 1.12 — the most call-skewed reading in at least a year for a stock that habitually runs a PCR above 1.1. Where the pre-earnings articles noted that call-side enthusiasm had briefly appeared and then faded back to neutral by July 24, the post-earnings session has locked in a sustained shift. The ORTEX short score has also drifted down to 57.4 from 60.8 a week ago, reflecting the combined effect of covering and price appreciation — still elevated in absolute terms, but moving in the right direction for longs.
The Street is playing catch-up from a low base. JP Morgan kept its Overweight rating but slashed its target from $74 to $55 on July 24, just days before the stock closed at $50.31 — meaning the post-earnings rally has already consumed most of the gap that cut implied. Guggenheim similarly maintained Buy but trimmed to $65 from $80 on July 27. The pattern across recent weeks has been uniform: virtually every firm to act has cut targets while holding ratings, leaving a consensus mean target of $60.38 that now implies only around 20% upside from current levels. That is a dramatically tighter setup than the 63% upside gap flagged in earlier ORTEX notes when the stock was trading below $40. The valuation has re-rated sharply — the P/E has expanded roughly 1.9 turns over 30 days to 8.4x, and EV/EBITDA has moved up around 0.32 turns to 5.4x — both still cheap in absolute terms but no longer the distressed-multiple situation of a month ago.
The fundamental debate remains unresolved. Bulls point to the Astreya acquisition, the AI Factory platform, and improving hyperscaler relationships as signs the company is repositioning toward higher-growth work. The EV/EBIT factor score ranks in the 96th percentile of the ORTEX universe, and forward EPS estimates are up year-on-year — the 12-month forward EPS growth score ranks 83rd percentile. Bears counter with execution risk on large deal integration, productivity-driven pricing pressure from clients, and ongoing talent challenges in a competitive offshore labour market. The one prior earnings reaction in the data — a 6.4% drop on June 2 — was the setup heading into July 29; the actual Q2 reaction has now replaced that as the most recent data point, and it is sharply the other way.
The key question from here is whether the analyst community follows the stock higher with target raises — or whether the consensus, still anchored to cuts from the past six weeks, creates a ceiling around $55–$60 that caps near-term momentum for CTSH. Close peers ACN and EPAM both gained over 12% on the week, suggesting sector-wide relief rather than a company-specific catalyst alone, which will shape how durable this move proves to be.
See the live data behind this article on ORTEX.
Open CTSH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
